阿米卡星
粘菌素
鲍曼不动杆菌
铜绿假单胞菌
抗生素
医学
抗菌剂
肺炎
药理学
微生物学
重症监护医学
生物
细菌
内科学
遗传学
作者
Claudia Vairo,Maria Villar Vidal,Rosa María Hernández,Manoli Igartua,Silvia Villullas
标识
DOI:10.1016/j.ijpharm.2023.122739
摘要
Antimicrobial resistance (AMR) is a global health issue, which needs to be tackled without further delay. The World Health Organization(WHO) has classified three gram-negative bacteria, Pseudomonas aeruginosa, Klebsiella pneumonia and Acinetobacter baumannii, as the principal responsible for AMR, mainly causing difficult to treat nosocomial lung and wound infections. In this regard, the need for colistin and amikacin, the re-emerged antibiotics of choice for resistant gram-negative infections, will be examined as well as their associated toxicity. Thus, current but ineffective clinical strategies designed to prevent toxicity related to colistin and amikacin will be reported, highlighting the importance of lipid-based drug delivery systems (LBDDSs), such as liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), as efficient delivery strategies for reducing antibiotic toxicity. This review reveals that colistin- and amikacin-NLCs are promising carriers with greater potential than liposomes and SLNs to safely tackle AMR, especially for lung and wound infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI